PACS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2026Q1

1.38B

+14.5%

0.470

+435.31%

1.38B

+8.08%

0.397

+27.61%

Estimates Revision

The market is revising Upward the revenue expectations for PACS Group, Inc. (PACS) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by 215.73%.

Revenue Estimates for FY2025

Revise Upward

+0.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.59%

In Past 3 Month

Stock Price

Go Up

+215.73%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast PACS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACS is 32.50 USD with a low forecast of 32.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

32.00

Averages

32.50

High

33.00

Current: 0.000

Low

32.00

Averages

32.50

High

33.00

Truist

David MacDonald

Buy

downgrade

$48 -> $40

2026-01-05

New

Reason

Truist

David MacDonald

Price Target

$48 -> $40

2026-01-05

New

downgrade

Buy

Reason

Truist analyst David MacDonald lowered the firm's price target on Pacs Group to $40 from $48 and keeps a Buy rating on the shares. Pacs Group is well-positioned into 2026 following the November conclusion of the Audit Committee investigation with committee recommendations having been or being implemented, the analyst tells investors in a research note.

UBS

NULL -> Buy

downgrade

$50 -> $42

2025-12-18

Reason

UBS

Price Target

$50 -> $42

2025-12-18

downgrade

NULL -> Buy

Reason

UBS resumed coverage of Pacs Group with a Buy rating with a price target of $42, down from $50. Pacs is well-positioned to take advantage of industry tailwinds that include an aging U.S. population, shifts to lower cost site of care settings, and a fragmented industry that provides ample acquisition opportunities of low performing facilities, the analyst tells investors in a research note. The current valuation reflects a few outstanding regulatory and legal issues and fundamentals are holding strong, the firm adds.

JPMorgan

NULL

Overweight

initiated

$44

2025-12-17

Reason

JPMorgan

Price Target

$44

2025-12-17

initiated

NULL

Overweight

Reason

JPMorgan reinstated coverage of Pacs Group with an Overweight rating and $44 price target following a period of restriction. The firm believes Pacs has an attractive business model centered around acquiring underperforming skilled nursing facilities and capturing earnings through improvements to clinical, operational, and financial performance.

Truist

Buy

maintain

$32 -> $40

2025-12-12

Reason

Truist

Price Target

$32 -> $40

2025-12-12

maintain

Buy

Reason

Truist raised the firm's price target on Pacs Group to $40 from $32 and keeps a Buy rating on the shares. The firm remains bullish on the stock following upbeat management meetings highlighting the company's strong positioning, enhanced compliance/regulatory rigor post completion of the internal investigation, and attractive underlying trends, the analyst tells investors in a research note. Ongoing expansion activity further complements the solid core trends at Pacs, Truist added.

Valuation Metrics

The current forward P/E ratio for Pacs Group Inc (PACS.N) is 20.36, compared to its 5-year average forward P/E of 12.47. For a more detailed relative valuation and DCF analysis to assess Pacs Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.47

Current PE

20.36

Overvalued PE

18.80

Undervalued PE

6.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.27

Current EV/EBITDA

18.28

Overvalued EV/EBITDA

18.68

Undervalued EV/EBITDA

9.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.75

Current PS

1.10

Overvalued PS

1.15

Undervalued PS

0.35

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PACS News & Events

Events Timeline

No data

News

4.5

2025-12-22SeekingAlpha

PACS Group Leads Healthcare Facilities Stocks in Year-to-Date Performance

4.5

2025-12-03NASDAQ.COM

Wednesday's Underperforming Sectors: Technology, Healthcare Facilities, and Medical Professionals

8.5

2025-12-01Businesswire

PACS Group Acquires 160-Bed Skilled Nursing Facility in Nevada, Expanding Market Presence

People Also Watch

Frequently Asked Questions

What is Pacs Group Inc (PACS) stock price today?

The current price of PACS is 41.36 USD — it has increased 0.44 % in the last trading day.

What is Pacs Group Inc (PACS)'s business?

PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. The Company is focused on delivering skilled nursing care through a portfolio of independently operated facilities. It also provides its independently operated facilities with a comprehensive suite of technology, support, and back-office services. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after they have been discharged from the hospital. This ecosystem ranges from higher acuity, higher-cost settings, such as long-term acute care hospitals and inpatient rehabilitation facilities, to lower acuity, lower-cost settings, such as assisted living facilities, and home health. The Company’s independent subsidiaries operate about 314 post-acute care and senior living facilities across 17 states, serving over 30,000 patients daily.

What is the price predicton of PACS Stock?

What is Pacs Group Inc (PACS)'s revenue for the last quarter?

Pacs Group Inc revenue for the last quarter amounts to 1.34B USD, increased 31.01 % YoY.

What is Pacs Group Inc (PACS)'s earnings per share (EPS) for the last quarter?

Pacs Group Inc. EPS for the last quarter amounts to 0.32 USD, increased 220.00 % YoY.

What changes have occurred in the market's expectations for Pacs Group Inc (PACS)'s fundamentals?

How many employees does Pacs Group Inc (PACS). have?

Pacs Group Inc (PACS) has 45680 emplpoyees as of January 09 2026.

What is Pacs Group Inc (PACS) market cap?

Today PACS has the market capitalization of 6.48B USD.